AbCellera Biologics Inc. — Director's Dealing 2025

Jan 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AbCellera Biologics Inc. (ABCL)
CIK: 0001703057
Period of Report: 2025-01-01

Reporting Person: Lecault Veronique (Director, Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-01	Share option (right to buy)	$2.93	A	832033	Acquired	2035-01-01	Common Shares (832033)	Direct

Footnotes

F1: The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.